The challenges of combinatory immunotherapy for biliary tract cancer

Expert Opin Investig Drugs. 2021 Jun;30(6):591-594. doi: 10.1080/13543784.2021.1916467. Epub 2021 Apr 19.

Authors

Daniel Neureiter^{1

2}, Christian Mayr^{3

4}, Tobias Kiesslich^{3

4}

Affiliations

¹ Institute of Pathology, University Clinics Salzburg, Paracelsus Medical University, Salzburg, Austria.
² Cancer Cluster Salzburg, Cancer Cluster Salzburg, Salzburg, Austria.
³ Department of Internal Medicine I, University Clinics Salzburg, Paracelsus Medical University, Salzburg, Austria.
⁴ Institute of Physiology and Pathophysiology, Paracelsus Medical University, Salzburg, Austria.

PMID: 33874822
DOI: 10.1080/13543784.2021.1916467

No abstract available

Keywords: Biliary tract cancer; immunogenicity; immunotherapy; therapy combination.

Publication types

Editorial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / immunology
Biliary Tract Neoplasms / immunology
Biliary Tract Neoplasms / therapy*
Humans
Immune Checkpoint Inhibitors / administration & dosage
Immunotherapy / methods*

Substances

Immune Checkpoint Inhibitors